Abstract
Tapping into the blossoming field of immunometabolism, Rheos Medicines has come out of stealth with $60 million in funding from Third Rock Ventures. The Cambridge, Mass.-based biotech firm will initially develop small molecules to treat autoimmune diseases such as inflammatory bowel disease, vitiligo, and lupus. While many areas of drug development are moving toward personalized medicine—most notably in cancer, where targeted therapy has proliferated—immunologists still rely on one-size-fits-all treatments for their patients. Rheos hopes to change that. Starting last summer, the company assembled a drug discovery platform based on findings from its academic founders, whose work focuses on how a cell’s metabolic pathways can control its fate. Cells, like people, get their energy from different sources, explains Rheos’s chief scientific officer, Laurence Turka. “You know how you feel different if you have two slices of pizza for lunch instead of a salad? You behave differently.” Cells are no different, he
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call